Scroll

vandetanib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
angiogenesis inhibitors	4178	443913-73-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ZD-6474 vandetanib zactima caprelsa ZD6474	In vitro studies have shown that vandetanib inhibits the tyrosine kinase activity of the EGFR and VEGFR families, RET, BRK, TIE2, and members of the EPH receptor and Src kinase families. These receptor tyrosine kinases are involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment. In addition, the N-desmethyl metabolite of the drug, representing 7 to 17.1% of vandetanib exposure, has similar inhibitory activity to the parent compound for VEGF receptors (KDR and Flt-1) and EGFR. In vitro, vandetanib inhibited epidermal growth factor (EGF)-stimulated receptor tyrosine kinase phosphorylation in tumor cells and endothelial cells and VEGF-stimulated tyrosine kinase phosphorylation in endothelial cells. In vivo, vandetanib administration reduced tumor cell-induced angiogenesis, tumor vessel permeability, and inhibited tumor growth and metastasis in mouse models of cancer. Molecular weight: 475.36 Formula: C22H24BrFN4O2 CLOGP: 5.69 LIPINSKI: 1 HAC: 6 HDO: 1 TPSA: 59.51 ALOGS: -4.67 ROTB: 6 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

ZD-6474
vandetanib
zactima
caprelsa
ZD6474

In vitro studies have shown that vandetanib inhibits the tyrosine kinase activity of the EGFR and VEGFR families, RET, BRK, TIE2, and members of the EPH receptor and Src kinase families. These receptor tyrosine kinases are involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment. In addition, the N-desmethyl metabolite of the drug, representing 7 to 17.1% of vandetanib exposure, has similar inhibitory activity to the parent compound for VEGF receptors (KDR and Flt-1) and EGFR. In vitro, vandetanib inhibited epidermal growth factor (EGF)-stimulated receptor tyrosine kinase phosphorylation in tumor cells and endothelial cells and VEGF-stimulated tyrosine kinase phosphorylation in endothelial cells. In vivo, vandetanib administration reduced tumor cell-induced angiogenesis, tumor vessel permeability, and inhibited tumor growth and metastasis in mouse models of cancer.

Molecular weight: 475.36
Formula: C22H24BrFN4O2
CLOGP: 5.69
LIPINSKI: 1
HAC: 6
HDO: 1
TPSA: 59.51
ALOGS: -4.67
ROTB: 6

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.30	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Hosey CM, Chan R, Benet LZ

Approvals:

Date	Agency	Company	Orphan
April 6, 2011	FDA	IPR PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Electrocardiogram QT prolonged	133.34	35.93	50	1254	51836	50551984
Reflux gastritis	75.85	35.93	14	1290	879	50602941
Hypophosphataemia	61.88	35.93	18	1286	8396	50595424
Lymphocyte count decreased	55.41	35.93	22	1282	26285	50577535
Facial paralysis	54.56	35.93	18	1286	12697	50591123
Ataxia	53.13	35.93	18	1286	13768	50590052
Blood triglycerides increased	52.52	35.93	17	1287	11295	50592525
Myoclonus	52.28	35.93	18	1286	14452	50589368
Hemiparesis	46.55	35.93	18	1286	20030	50583790
Ocular hyperaemia	46.34	35.93	18	1286	20274	50583546
Hypophagia	44.18	35.93	19	1285	27709	50576111
Disease progression	42.70	35.93	28	1276	95838	50507982
Malignant neoplasm progression	40.72	35.93	24	1280	68100	50535720
Neutrophil count decreased	40.69	35.93	21	1283	46005	50557815
Flatulence	39.86	35.93	18	1286	29440	50574380
Metastases to liver	36.09	35.93	15	1289	20089	50583731

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Electrocardiogram QT prolonged	83.80	35.42	29	481	36108	29537909
Blood calcitonin increased	52.33	35.42	6	504	15	29574002

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Electrocardiogram QT prolonged	160.41	32.33	65	1666	79383	64417618
Reflux gastritis	73.68	32.33	14	1717	986	64496015
Blood calcitonin increased	54.32	32.33	7	1724	34	64496967
Hypophosphataemia	51.23	32.33	18	1713	14702	64482299
Myoclonus	48.58	32.33	20	1711	25098	64471903
Facial paralysis	46.78	32.33	18	1713	18948	64478053
Lymphocyte count decreased	45.28	32.33	22	1709	40677	64456324
Malignant neoplasm progression	44.35	32.33	31	1700	112840	64384161
Ataxia	44.12	32.33	18	1713	22066	64474935
Ocular hyperaemia	43.75	32.33	18	1713	22546	64474455
Blood triglycerides increased	43.32	32.33	17	1714	18849	64478152
Metastases to liver	42.72	32.33	18	1713	23923	64473078
Metastases to bone	42.00	32.33	17	1714	20418	64476583
Hemiparesis	38.92	32.33	18	1713	29809	64467192
Flatulence	38.83	32.33	19	1712	35647	64461354
Hypophagia	36.95	32.33	19	1712	39568	64457433
Diarrhoea	34.86	32.33	66	1665	722638	63774363
Blood cholesterol increased	32.77	32.33	19	1712	50047	64446954

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01EX04	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Other protein kinase inhibitors
FDA MoA	N0000175076	Protein Kinase Inhibitors
FDA EPC	N0000175605	Kinase Inhibitor
FDA MoA	N0000185503	P-Glycoprotein Inhibitors
FDA MoA	N0000187061	Organic Cation Transporter 2 Inhibitors
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:38637	tyrosine kinase inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Carcinoma of thyroid	indication	448216007
Hypocalcemia	contraindication	5291005
Torsades de pointes	contraindication	31722008
Hypertensive disorder	contraindication	38341003	DOID:10763
Hypothyroidism	contraindication	40930008	DOID:1459
Hypokalemia	contraindication	43339004
Heart failure	contraindication	84114007	DOID:6000
Prolonged QT interval	contraindication	111975006
Hypomagnesemia	contraindication	190855004
Impaired renal function disorder	contraindication	197663003
Interstitial lung disease	contraindication	233703007	DOID:3082
Cerebral ischemia	contraindication	287731003
Pregnancy, function	contraindication	289908002
Severe diarrhea	contraindication	409587002
Breastfeeding (mother)	contraindication	413712001
Congenital long QT syndrome	contraindication	442917000
Posterior reversible encephalopathy syndrome	contraindication	450886002
Significant Bleeding	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.58	Basic
pKa2	5.88	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
100MG	CAPRELSA	GENZYME CORP	N022405	April 6, 2011	RX	TABLET	ORAL	8642608	Feb. 6, 2022	FOR USE IN PATIENTS HAVING SYMPTOMATIC OR PROGRESSIVE MEDULLARY THYROID CANCER, WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC DISEASE
300MG	CAPRELSA	GENZYME CORP	N022405	April 6, 2011	RX	TABLET	ORAL	8642608	Feb. 6, 2022	FOR USE IN PATIENTS HAVING SYMPTOMATIC OR PROGRESSIVE MEDULLARY THYROID CANCER, WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC DISEASE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Proto-oncogene tyrosine-protein kinase receptor Ret	Kinase	P07949	RET_HUMAN	INHIBITOR	Kd	7.85	CHEMBL	CHEMBL
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN	INHIBITOR	Kd	8.32	CHEMBL	CHEMBL
Vascular endothelial growth factor receptor 2	Kinase	P35968	VGFR2_HUMAN	INHIBITOR	Kd	6.33	CHEMBL	CHEMBL
Tyrosine-protein kinase ABL1	Kinase	P00519	ABL1_HUMAN		Kd	8.05	CHEMBL
Mast/stem cell growth factor receptor Kit	Kinase	P10721	KIT_HUMAN		Kd	7.47	CHEMBL
Breakpoint cluster region protein	Kinase	P11274	BCR_HUMAN		Kd	6.06	CHEMBL
Proto-oncogene tyrosine-protein kinase Src	Kinase	P12931	SRC_HUMAN	INHIBITOR	Kd	7.15	CHEMBL
Tyrosine-protein kinase Lck	Kinase	P06239	LCK_HUMAN		Kd	7.77	CHEMBL
Tyrosine-protein kinase Fyn	Kinase	P06241	FYN_HUMAN		Kd	6.44	CHEMBL
Ephrin type-A receptor 2	Kinase	P29317	EPHA2_HUMAN	INHIBITOR	Kd	5.96	CHEMBL
Receptor-type tyrosine-protein kinase FLT3	Kinase	P36888	FLT3_HUMAN		Kd	6.72	CHEMBL
Vascular endothelial growth factor receptor 1	Kinase	P17948	VGFR1_HUMAN	INHIBITOR	Kd	6.59	CHEMBL
Vascular endothelial growth factor receptor 3	Kinase	P35916	VGFR3_HUMAN	INHIBITOR	Kd	6.52	CHEMBL
Macrophage colony-stimulating factor 1 receptor	Kinase	P07333	CSF1R_HUMAN		Kd	5.92	CHEMBL
Platelet-derived growth factor receptor alpha	Kinase	P16234	PGFRA_HUMAN		Kd	6.64	CHEMBL
Receptor tyrosine-protein kinase erbB-2	Kinase	P04626	ERBB2_HUMAN	INHIBITOR	Kd	5.59	CHEMBL
Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	Kinase	P15735	PHKG2_HUMAN		Kd	5.10	CHEMBL
Fibroblast growth factor receptor 3	Kinase	P22607	FGFR3_HUMAN		Kd	6.62	CHEMBL
Tyrosine-protein kinase HCK	Kinase	P08631	HCK_HUMAN		Kd	6.44	CHEMBL
Receptor tyrosine-protein kinase erbB-4	Kinase	Q15303	ERBB4_HUMAN	INHIBITOR	Kd	6.32	CHEMBL
Rho-associated protein kinase 2	Kinase	O75116	ROCK2_HUMAN		Kd	5.44	CHEMBL
Tyrosine-protein kinase CSK	Kinase	P41240	CSK_HUMAN		Kd	5.60	CHEMBL
Angiopoietin-1 receptor	Kinase	Q02763	TIE2_HUMAN	INHIBITOR	Kd	6	CHEMBL
Ephrin type-A receptor 8	Kinase	P29322	EPHA8_HUMAN	INHIBITOR	Kd	7.04	CHEMBL
Hepatocyte growth factor receptor	Kinase	P08581	MET_HUMAN		Kd	5.39	CHEMBL
Tyrosine-protein kinase Lyn	Kinase	P07948	LYN_HUMAN		Kd	6.96	CHEMBL
5'-AMP-activated protein kinase catalytic subunit alpha-1	Kinase	Q13131	AAPK1_HUMAN		Kd	5.52	CHEMBL
Fibroblast growth factor receptor 1	Kinase	P11362	FGFR1_HUMAN		Kd	6.25	CHEMBL
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform	Kinase	Q16816	PHKG1_HUMAN		Kd	5.96	CHEMBL
Serine/threonine-protein kinase 10	Kinase	O94804	STK10_HUMAN		Kd	7.09	CHEMBL
Serine/threonine-protein kinase PLK4	Kinase	O00444	PLK4_HUMAN		Kd	6.21	CHEMBL
Aurora kinase C	Kinase	Q9UQB9	AURKC_HUMAN		Kd	5.82	CHEMBL
Abelson tyrosine-protein kinase 2	Kinase	P42684	ABL2_HUMAN		Kd	7.16	CHEMBL
Ephrin type-A receptor 5	Kinase	P54756	EPHA5_HUMAN	INHIBITOR	Kd	6.62	CHEMBL
Ephrin type-A receptor 4	Kinase	P54764	EPHA4_HUMAN	INHIBITOR	Kd	5.80	CHEMBL
Fibroblast growth factor receptor 2	Kinase	P21802	FGFR2_HUMAN		Kd	5.96	CHEMBL
Ephrin type-A receptor 6	Kinase	Q9UF33	EPHA6_HUMAN	INHIBITOR	Kd	7.30	CHEMBL
TRAF2 and NCK-interacting protein kinase	Kinase	Q9UKE5	TNIK_HUMAN		Kd	5.64	CHEMBL
Casein kinase I isoform epsilon	Kinase	P49674	KC1E_HUMAN		Kd	5.82	CHEMBL
Tyrosine-protein kinase Fgr	Kinase	P09769	FGR_HUMAN		Kd	6.57	CHEMBL
ALK tyrosine kinase receptor	Kinase	Q9UM73	ALK_HUMAN		Kd	5.68	CHEMBL
Ephrin type-A receptor 3	Kinase	P29320	EPHA3_HUMAN	INHIBITOR	Kd	5.74	CHEMBL
Tyrosine-protein kinase FRK	Kinase	P42685	FRK_HUMAN		Kd	6.77	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 5	Kinase	Q9Y4K4	M4K5_HUMAN		Kd	6.35	CHEMBL
Mitogen-activated protein kinase kinase kinase 4	Kinase	Q9Y6R4	M3K4_HUMAN		Kd	5.52	CHEMBL
Cyclin-G-associated kinase	Kinase	O14976	GAK_HUMAN		Kd	7.07	CHEMBL
Receptor-interacting serine/threonine-protein kinase 2	Kinase	O43353	RIPK2_HUMAN		Kd	8.34	CHEMBL
Ephrin type-B receptor 1	Kinase	P54762	EPHB1_HUMAN	INHIBITOR	Kd	6.54	CHEMBL
Ephrin type-A receptor 7	Kinase	Q15375	EPHA7_HUMAN	INHIBITOR	Kd	5.62	CHEMBL
STE20-like serine/threonine-protein kinase	Kinase	Q9H2G2	SLK_HUMAN		Kd	7.02	CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 2	Kinase	Q9HBH9	MKNK2_HUMAN		Kd	5.77	CHEMBL
Epithelial discoidin domain-containing receptor 1	Kinase	Q08345	DDR1_HUMAN		Kd	7.96	CHEMBL
Ephrin type-B receptor 4	Kinase	P54760	EPHB4_HUMAN	INHIBITOR	Kd	6.28	CHEMBL
Serine/threonine-protein kinase receptor R3	Kinase	P37023	ACVL1_HUMAN		Kd	6.33	CHEMBL
Activin receptor type-1	Kinase	Q04771	ACVR1_HUMAN		Kd	6.82	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 1	Kinase	Q02750	MP2K1_HUMAN		Kd	5.74	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 2	Kinase	P36507	MP2K2_HUMAN		Kd	5.96	CHEMBL
Protein-tyrosine kinase 6	Kinase	Q13882	PTK6_HUMAN	INHIBITOR	Kd	7.48	CHEMBL
Tyrosine-protein kinase BTK	Kinase	Q06187	BTK_HUMAN		Kd	5.77	CHEMBL
Tyrosine-protein kinase receptor UFO	Kinase	P30530	UFO_HUMAN		Kd	6.60	CHEMBL
Tyrosine-protein kinase receptor TYRO3	Kinase	Q06418	TYRO3_HUMAN		Kd	7.03	CHEMBL
Ephrin type-B receptor 2	Kinase	P29323	EPHB2_HUMAN	INHIBITOR	Kd	6.36	CHEMBL
Cyclin-dependent kinase 7	Kinase	P50613	CDK7_HUMAN		Kd	5.39	CHEMBL
Ribosomal protein S6 kinase beta-1	Kinase	P23443	KS6B1_HUMAN		Kd	5.80	CHEMBL
Ribosomal protein S6 kinase alpha-6	Kinase	Q9UK32	KS6A6_HUMAN		Kd	6.62	CHEMBL
Mitogen-activated protein kinase kinase kinase MLT	Kinase	Q9NYL2	MLTK_HUMAN		Kd	5.29	CHEMBL
Tyrosine-protein kinase receptor Tie-1	Kinase	P35590	TIE1_HUMAN		Kd	5.82	CHEMBL
Tyrosine-protein kinase TXK	Kinase	P42681	TXK_HUMAN		Kd	5.43	CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 1	Kinase	Q9BUB5	MKNK1_HUMAN		Kd	6.44	CHEMBL
Serine/threonine-protein kinase SIK2	Kinase	Q9H0K1	SIK2_HUMAN		Kd	6.37	CHEMBL
Serine/threonine-protein kinase 33	Kinase	Q9BYT3	STK33_HUMAN		Kd	5.85	CHEMBL
Serine/threonine-protein kinase TNNI3K	Kinase	Q59H18	TNI3K_HUMAN		Kd	5.55	CHEMBL
Discoidin domain-containing receptor 2	Kinase	Q16832	DDR2_HUMAN		Kd	6.49	CHEMBL
Chaperone activity of bc1 complex-like, mitochondrial	Kinase	Q8NI60	COQ8A_HUMAN		Kd	5.35	CHEMBL
Serine/threonine-protein kinase MRCK gamma	Kinase	Q6DT37	MRCKG_HUMAN		Kd	5.66	CHEMBL
Leukocyte tyrosine kinase receptor	Kinase	P29376	LTK_HUMAN		Kd	6.26	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 1	Kinase	Q92918	M4K1_HUMAN		Kd	5.26	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 3	Kinase	Q8IVH8	M4K3_HUMAN		Kd	5.82	CHEMBL
Tyrosine-protein kinase Blk	Kinase	P51451	BLK_HUMAN		Kd	7.18	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 4	Kinase	O95819	M4K4_HUMAN		Kd	5.85	CHEMBL
Tyrosine-protein kinase Mer	Kinase	Q12866	MERTK_HUMAN		Kd	5.85	CHEMBL
Serine/threonine-protein kinase MRCK alpha	Kinase	Q5VT25	MRCKA_HUMAN		Kd	5.59	CHEMBL
Serine/threonine-protein kinase MRCK beta	Kinase	Q9Y5S2	MRCKB_HUMAN		Kd	5.60	CHEMBL
Citron Rho-interacting kinase	Kinase	O14578	CTRO_HUMAN		Kd	5.74	CHEMBL
AarF domain-containing protein kinase 4	Kinase	Q96D53	COQ8B_HUMAN		Kd	5.77	CHEMBL
Serine/threonine-protein kinase SIK1	Kinase	P57059	SIK1_HUMAN		Kd	5.72	CHEMBL
Tyrosine-protein kinase Srms	Kinase	Q9H3Y6	SRMS_HUMAN		Kd	5.72	CHEMBL
Dual specificity testis-specific protein kinase 1	Kinase	Q15569	TESK1_HUMAN		Kd	5.43	CHEMBL
Ephrin type-A receptor 1	Kinase	P21709	EPHA1_HUMAN	INHIBITOR	Kd	6.64	CHEMBL
Mitogen-activated protein kinase 6	Kinase	Q16659	MK06_HUMAN		Kd	5.82	CHEMBL
Fibroblast growth factor receptor 4	Kinase	P22455	FGFR4_HUMAN		Kd	5.64	CHEMBL
Ribosomal protein S6 kinase alpha-1	Kinase	Q15418	KS6A1_HUMAN		Kd	6.40	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 2	Kinase	Q12851	M4K2_HUMAN		Kd	5.80	CHEMBL
Misshapen-like kinase 1	Kinase	Q8N4C8	MINK1_HUMAN		Kd	5.47	CHEMBL
Interleukin-1 receptor-associated kinase 4	Kinase	Q9NWZ3	IRAK4_HUMAN		Kd	7.12	CHEMBL
Ephrin type-B receptor 6	Kinase	O15197	EPHB6_HUMAN	INHIBITOR	Kd	7.12	CHEMBL
Hormonally up-regulated neu tumor-associated kinase	Kinase	P57058	HUNK_HUMAN		Kd	5.39	CHEMBL
Interleukin-1 receptor-associated kinase 1	Kinase	P51617	IRAK1_HUMAN		Kd	5.92	CHEMBL
Serine/threonine-protein kinase ULK3	Kinase	Q6PHR2	ULK3_HUMAN		Kd	5.19	CHEMBL
Mitogen-activated protein kinase kinase kinase 19	Kinase	Q56UN5	M3K19_HUMAN		Kd	6.01	CHEMBL
Receptor-interacting serine/threonine-protein kinase 4	Kinase	P57078	RIPK4_HUMAN		Kd	6.21	CHEMBL
Serine/threonine-protein kinase 35	Kinase	Q8TDR2	STK35_HUMAN		Kd	7.25	CHEMBL
Receptor tyrosine-protein kinase erbB-3	Kinase	P21860	ERBB3_HUMAN	INHIBITOR	Kd	6.80	CHEMBL
Serine/threonine-protein kinase SIK3	Kinase	Q9Y2K2	SIK3_HUMAN		Kd	5.41	CHEMBL
Bone morphogenetic protein receptor type-1B	Kinase	O00238	BMR1B_HUMAN		Kd	6.62	CHEMBL
Serine/threonine-protein kinase 32A	Kinase	Q8WU08	ST32A_HUMAN		Kd	5.30	CHEMBL
Tyrosine-protein kinase Yes	Kinase	P07947	YES_HUMAN		Kd	6.92	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5	Kinase	Q13163	MP2K5_HUMAN		Kd	7.31	CHEMBL
Macrophage-stimulating protein receptor	Kinase	Q04912	RON_HUMAN		IC50	5.47	CHEMBL
Platelet-derived growth factor receptor beta	Kinase	P09619	PGFRB_HUMAN		Kd	7.06	CHEMBL
Tubulin alpha-1A chain	Structural		TBA1A_RAT		Kd	6.32	CHEMBL

External reference:

ID	Source
4030726	VUID
N0000182736	NUI
D06407	KEGG_DRUG
4030726	VANDF
C1121849	UMLSCUI
CHEBI:49960	CHEBI
ZD6	PDB_CHEM_ID
CHEMBL24828	ChEMBL_ID
DB05294	DRUGBANK_ID
C452423	MESH_SUPPLEMENTAL_RECORD_UI
5717	IUPHAR_LIGAND_ID
8365	INN_ID
YO460OQ37K	UNII
3081361	PUBCHEM_CID
1098413	RXNORM
181099	MMSL
189346	MMSL
27846	MMSL
d07761	MMSL
013703	NDDF
418260004	SNOMEDCT_US
418520004	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
CAPRELSA	HUMAN PRESCRIPTION DRUG LABEL	1	58468-7820	TABLET, FILM COATED	100 mg	ORAL	NDA	32 sections
CAPRELSA	HUMAN PRESCRIPTION DRUG LABEL	1	58468-7820	TABLET, FILM COATED	100 mg	ORAL	NDA	32 sections
CAPRELSA	HUMAN PRESCRIPTION DRUG LABEL	1	58468-7840	TABLET, FILM COATED	300 mg	ORAL	NDA	32 sections
CAPRELSA	HUMAN PRESCRIPTION DRUG LABEL	1	58468-7840	TABLET, FILM COATED	300 mg	ORAL	NDA	32 sections